NCT06172595招募中2 期
18F-FET (O-(2-[18F]Fluoroethyl)-L-tyrosine) PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Gliomas
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 22
- 试验地点
- 2
- 主要终点
- Performance characteristics of FET PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional imaging
研究概览
简要总结
The goal of this clinical trial is to evaluate the performance characteristics of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional imaging and determine the sensitivity and specificity of [18F]FET-PET in delineating disease. The main question[s] it aims to answer are:
- whether 18F-FET-PET will demonstrate high diagnostic accuracy to detect true tumour progression
- whether we can optimise the threshold cut-offs for TBRmax and other relevant parameters in discriminating pseudoprogression and disease progression Participants will undergo a limited 18F-FET PET/CT of the brain in SGH.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or Women, aged 21 years or older at time of screening
- •Histologically confirmed diagnosis of malignant glioma (defined as WHO grade III or IV) with previous RT to tumour
- •With enlarging contrast-enhancing and/or T2W/FLAIR-hyperintense lesion(s) on MRI within the previous RT field
- •Gliomas with Isocitrate dehydrogenase (IDH) wild-type status, as defined on immunohistochemistry
- •Subject must consent to undergo all study procedures
排除标准
- •Low-grade gliomas (histology grade 1 or 2 by WHO classification)16,17
- •Previous bevacizumab or other vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments.
- •Proven cerebral metastases
- •IDH-mutated gliomas
- •Pregnancy/ breast-feeding
结局指标
主要结局
Performance characteristics of FET PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional imaging
时间窗: 1 year
Sensitivity and specificity of \[18F\]FET-PET in delineating disease.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Molecular Pituitary Imaging Using 18F-FET PETPituitary AdenomaNCT06584123University of Cambridge20
招募中
1 期
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast CancerAnatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaNCT06502691University of Washington22
已完成
不适用
18F-FET PET/CT in the Management of GliomaGliomaNCT06563024Buddhist Tzu Chi General Hospital36
已完成
早期 1 期
18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing SarcomaAdult Supratentorial Primitive Neuroectodermal Tumor (PNET)Ewing Sarcoma of BoneExtraosseous Ewing SarcomaLocalized Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorUntreated Childhood Supratentorial Primitive Neuroectodermal TumorNCT01825902Mayo Clinic1
终止
早期 1 期
18F-FES PET/CT in Imaging Patients With Desmoid TumorsDeep Fibromatosis/Desmoid TumorFamilial Adenomatous PolyposisNCT02374931Vanderbilt-Ingram Cancer Center3